Pretreatment of Endothelial Progenitor Cells With Osteopontin Enhances Cell Therapy for Peripheral Vascular Disease

Cell Transplantation

Volumn 21, Issue 6, 2012, Pages 1095-1107

  Vaughan, E E ^a   Liew, A ^a   Mashayekhi, K ^a   Dockery, P ^a   Mcdermott, J ^a   Kealy, B ^a   Flynn, A ^a   Duffy, A ^b   Coleman, C ^a   O'Regan, A ^c   Barry, F P ^a   O'Brien, Timothy ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b Medtronic   (Ireland)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Diabetes mellitus; Endothelial progenitor cell (EPC); Ischemia; Osteopontin; Stem cell; Vascular disease

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR ALPHA; INTERLEUKIN 6; OSTEOPONTIN; RECOMBINANT OSTEOPONTIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOXAN DIABETES MELLITUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL ADHESION; CELL POPULATION; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DOWN REGULATION; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LASER DOPPLER FLOWMETRY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PERINATAL PERIOD; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION;

ADULT; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTORS; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOPONTIN; PERIPHERAL VASCULAR DISEASES; RABBITS; RECOMBINANT PROTEINS; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE THERAPY; TRANSFORMING GROWTH FACTOR ALPHA; YOUNG ADULT;

MURINAE; MUS;

EID: 84859624861     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368911X623880     Document Type: Article

References (35)

1. Adam, D. J.; Beard, J. D.; Cleveland, T.; Bell, J.; Bradbury, A. W.; Forbes, J. F.; Fowkes, F. G.; Gillepsie, I.; Ruckley, C. V.; Raab, G.; Storkey, H. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial. Lancet 366(9501): 1925-1934; 2005.
2. Asnaghi, V.; Lattanzio, R.; Mazzolari, G.; Pastore, M. R.; Ramoni, A.; Maestroni, A.; Ruggieri, D.; Luzi, L.; Brancato, R.; Zerbini, G. Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy. Diabetologia 49(5):1109-1111; 2006.
3. Assmus, B.; Schachinger, V.; Teupe, C.; Britten, M.; Lehmann, R.; Dobert, N.; Grunwald, F.; Aicher, A.; Urbich, C.; Martin, H.; Hoelzer, D.; Dimmeler, S.; Zeiher, A. M. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCAREAMI). Circulation 106(24):3009-3017; 2002.
4. Basile, D. P.; Fredrich, K.; Alausa, M.; Vio, C. P.; Liang, M.; Rieder, M. R.; Greene, A. S.; Cowley, Jr., A. W. Identification of persistently altered gene expression in the kidney after functional recovery from ischemic acute renal failure. Am. J. Physiol. Renal Physiol. 288(5):F953-963; 2005.
5. Denhardt, D. T.; Lopez, C. A.; Rollo, E. E.; Hwang, S. M.; An, X. R.; Walther, S. E. Osteopontin-induced modifications of cellular functions. Ann. NY Acad. Sci. 760:127-142; 1995.
6. Di Santo, S.; Yang, Z.; Wyler von Ballmoos, M.; Voelzmann, J.; Diehm, N.; Baumgartner, I.; Kalka, C. Novel cell-free strategy for therapeutic angiogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 4(5):e5643; 2009.
7. Duvall, C. L.; Taylor, W. R.; Weiss, D.; Wojtowicz, A. M.; Guldberg, R. E. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J. Bone Miner. Res. 22(2): 286-297; 2007.
8. Duvall, C. L.; Weiss, D.; Robinson, S. T.; Alameddine, F. M.; Guldberg, R. E.; Taylor, W. R. The role of osteopontin in recovery from hind limb ischemia. Arterioscler. Thromb. Vasc. Biol. 28(2):290-295; 2008.
9. Fadini, G. P.; Miorin, M.; Facco, M.; Bonamico, S.; Baesso, I.; Grego, F.; Menegolo, M.; de Kreutzenberg, S. V.; Tiengo, A.; Agostini, C.; Avogaro, A. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45(9):1449-1457; 2005.
10. Furger, K. A.; Menon, R. K.; Tuck, A. B.; Bramwell, V. H.; Chambers, A. F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1(5):621-632; 2001.
11. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K. F.; Goebel, M.; Hein, R.; Wester, H. J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2(3):e70; 2005.
12. Hirama, M.; Takahashi, F.; Takahashi, K.; Akutagawa, S.; Shimizu, K.; Soma, S.; Shimanuki, Y.; Nishio, K.; Fukuchi, Y. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 198(1):107-117; 2003.
13. Hu, Z.; Lin, D.; Yuan, J.; Xiao, T.; Zhang, H.; Sun, W.; Han, N.; Ma, Y.; Di, X.; Gao, M.; Ma, J.; Zhang, J.; Cheng, S.; Gao, Y. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin. Cancer Res. 11(13):4646-4652; 2005.
14. Hung, H. S.; Shyu, W. C.; Tsai, C. H.; Hsu, S. H.; Lin, S. Z. Transplantation of endothelial progenitor cells as therapeutics for cardiovascular diseases. Cell Transplant. 18(9):1003-1012; 2009.
15. Jeong, J. O.; Kim, M. O.; Kim, H.; Lee, M. Y.; Kim, S. W.; Ii, M.; Lee, J. U.; Lee, J.; Choi, Y. J.; Cho, H. J.; Lee, N.; Silver, M.; Wecker, A.; Kim, D. W.; Yoon, Y. S. Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation 119(5):699-708; 2009.
16. Kalka, C.; Masuda, H.; Takahashi, T.; Kalka-Moll, W. M.; Silver, M.; Kearney, M.; Li, T.; Isner, J. M.; Asahara, T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97(7):3422-3427; 2000.
17. Kim, J. Y.; Song, S. H.; Kim, K. L.; Maeng, Y. S.; Im, J. E.; Yie, S. W.; Ahn, Y. K.; Kim, D. K.; Suh, W. Human cord blood-derived endothelial progenitor cells and their conditioned media exhibit therapeutic equivalence for diabetic wound healing. Cell Transplant. 19(12):1635-1644; 2010.
18. Kossmehl, P.; Schonberger, J.; Shakibaei, M.; Faramarzi, S.; Kurth, E.; Habighorst, B.; von Bauer, R.; Wehland, M.; Kreutz, R.; Infanger, M.; Schulze-Tanzil, G.; Paul, M.; Grimm, D. Increase of fibronectin and osteopontin in porcine hearts following ischemia and reperfusion. J. Mol. Med. 83(8):626-637; 2005.
19. Kubota, Y.; Kishi, K.; Satoh, H.; Tanaka, T.; Nakajima, H.; Nakajima, T. Transplanted endothelial progenitor cells augment the survival areas of rat dorsal flaps. Cell Transplant. 12(6):647-657; 2003.
20. Kusaka, M.; Kuroyanagi, Y.; Mori, T.; Sasaki, H.; Maruyama, T.; Hayakawa, K.; Shiroki, R.; Kurahashi, H.; Hoshinaga, K. Up-regulation of osteopontin, chemokines, adhesion molecule, and heat shock proteins in 1-hour biopsy from cardiac death donor kidneys. Transplant. Proc. 38(10):3347-3350; 2006.
21. Lawall, H.; Bramlage, P.; Amann, B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb. Haemost. 103(4):696-709; 2010.
22. Lin, Z. Q.; Kondo, T.; Ishida, Y.; Takayasu, T.; Mukaida, N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J. Leukoc. Biol. 73(6):713-721; 2003.
23. Loomans, C. J.; de Koning, E. J.; Staal, F. J.; Rookmaaker, M. B.; Verseyden, C.; de Boer, H. C.; Verhaar, M. C.; Braam, B.; Rabelink, T. J.; van Zonneveld, A. J. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53(1):195-199; 2004.
24. Matoba, S.; Tatsumi, T.; Murohara, T.; Imaizumi, T.; Katsuda, Y.; Ito, M.; Saito, Y.; Uemura, S.; Suzuki, H.; Fukumoto, S.; Yamamoto, Y.; Onodera, R.; Teramukai, S.; Fukushima, M.; Matsubara, H. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am. Heart J. 156(5):1010-1018; 2008.
25. Mertelsmann, R.; Lindemann, A.; Oster, W.; Gamm, H.; Kolbe, K.; Herrmann, F. Hematopoietic growth factors in oncology. Cancer Detect. Prev. 14(6):613-616; 1990.
26. Schachinger, V.; Assmus, B.; Britten, M. B.; Honold, J.; Lehmann, R.; Teupe, C.; Abolmaali, N. D.; Vogl, T. J.; Hofmann, W. K.; Martin, H.; Dimmeler, S.; Zeiher, A. M. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 44(8):1690-1699; 2004.
27. Shevde, L. A.; Samant, R. S.; Paik, J. C.; Metge, B. J.; Chambers, A. F.; Casey, G.; Frost, A. R.; Welch, D. R. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin. Exp. Metastasis 23(2):123-133; 2006.
28. Shinozaki, M.; Okada, Y.; Kitano, A.; Ikeda, K.; Saika, S.; Shinozaki, M. Impaired cutaneous wound healing with excess granulation tissue formation in TNFalpha-null mice. Arch. Dermatol. Res. 301(7):531-537; 2009.
29. Tamarat, R.; Silvestre, J. S.; Le Ricousse-Roussanne, S.; Barateau, V.; Lecomte-Raclet, L.; Clergue, M.; Duriez, M.; Tobelem, G.; Levy, B. I. Impairment in ischemia-induced neovascularization in diabetes: Bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am. J. Pathol. 164(2): 457-466; 2004.
30. Tang, H.; Wang, J.; Bai, F.; Hong, L.; Liang, J.; Gao, J.; Zhai, H.; Lan, M.; Zhang, F.; Wu, K.; Fan, D. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem. Cell Biol. 85(1):103-110; 2007.
31. Tepper, O. M.; Galiano, R. D.; Capla, J. M.; Kalka, C.; Gagne, P. J.; Jacobowitz, G. R.; Levine, J. P.; Gurtner, G. C. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22): 2781-2786; 2002.
32. Uede, T.; Katagiri, Y.; Iizuka, J.; Murakami, M. Osteopontin, a coordinator of host defense system: A cytokine or an extracellular adhesive protein? Microbiol. Immunol. 41(9):641-648; 1997.
33. Urbich, C.; Aicher, A.; Heeschen, C.; Dernbach, E.; Hofmann, W. K.; Zeiher, A. M.; Dimmeler, S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39(5):733-742; 2005.
34. Wang, W.; Lin, S.; Xiao, Y.; Huang, Y.; Tan, Y.; Cai, L.; Li, X. Acceleration of diabetic wound healing with chitosan-crosslinked collagen sponge containing recombinant human acidic fibroblast growth factor in healing-impaired STZ diabetic rats. Life Sci. 82(3-4):190-204; 2008.
35. Zhao, X.; Johnson, J. N.; Singh, K.; Singh, M. Impairment of myocardial angiogenic response in the absence of osteopontin. Microcirculation 14(3):233-240; 2007.